AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Patients taking the diabetes drugs rosiglitazone and pioglitazone may be twice as likely to develop heart failure than patients who take alternative treatments, a large meta-analysis has suggested.
The authors said that the treatments should be re-evaluated by Nice, which currently recommends both drugs. Rosiglitazone (Avandia) and pioglitazone (Actos) were used by 1.5 million people in the UK last year.
Information leaflets provided with the drugs say that pioglitazone and rosiglitazone should not be taken by patients known to have heart failure, but the new results suggest that the drugs can provoke problems in patients with no history of the disease.…